Novo Nordisk, Clayton, North Carolina, US. New production facilities announced 24 June 2024. To be completed in 2027-2029.
Novo Nordisk
Both Eli Lilly and Novo Nordisk have invested in GLP-1 injectables manufacturing sites, with more capacity on the way.
With a ribbon-cutting ceremony and tour on June 14, 2024, Lilly showed off its newest manufacturing plant in Concord, NC, designed to help relieve manufacturing bottlenecks for injectable GLP-1 drugs Mounjaro and Zepbound. The company doubled its initial investment in the facility from $1 billion to $2 billion. At full capacity, the plant will employ approximately 600 people, with around 400 positions filled thus far.
